Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus DYCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus DYCILL.
BACTOCILL vs DYCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250 mg orally every 6 hours or 500 mg orally every 12 hours.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic